Virax Biolabs Group Ltd VRAX
Biotechnology: In Vitro & In Vivo Diagnostic Substances · IPO 2022 · data as of November 13, 2026
Virax Biolabs Group Ltd (VRAX) is a healthcare company listed in the US with a market value of about $823939. In fiscal year 2026 it had revenue of $12423 and net income of -$5M, a net margin of -40439.1%.
Its overall Stock Analiz score is 1.6 out of 5 (weak). The strongest part is financial health (4/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -84%.
About Virax Biolabs Group
Virax Biolabs Group is listed in the US and classified in biotechnology: in vitro & in vivo diagnostic substances, IPO year 2022. Revenue went from $123820 in 2021 to $12423 in 2026, a decline of about 36.9% a year. It was profitable in 0 of the last 6 years in our data. Its share count fell by 70% over three years (buybacks).
Score: 1.6 / 5
Checks passed
- Revenue growth above 10% last year
- Profit margin improving
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Interest covered more than 5 times
- Debt below 3 years of free cash flow
- Liabilities below 60% of assets
- Share count down over 3 years (buybacks)
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 6 years
| Fiscal year | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Revenue | $12423 | $6331 | $156419 | $8561 | $0 | $123820 |
| Net income | -$5M | -$6M | -$7M | -$5M | -$2M | -$650984 |
| Free cash flow | -$5M | -$5M | -$7M | — | — | — |
| EPS (diluted) | $-12.64 | $-4.51 | $-5.01 | $-4.06 | $-1.27 | $-0.48 |
| Net margin | -40439.1% | -95739.2% | -4304.8% | -63748.3% | — | -525.8% |
| ROIC | — | -105.8% | -95.6% | -49.6% | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Virax Biolabs Group pay a dividend?
Not currently.
Is Virax Biolabs Group a good stock to buy?
We do not give buy or sell advice. Virax Biolabs Group scores 1.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.